JP2006514054A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514054A5 JP2006514054A5 JP2004565490A JP2004565490A JP2006514054A5 JP 2006514054 A5 JP2006514054 A5 JP 2006514054A5 JP 2004565490 A JP2004565490 A JP 2004565490A JP 2004565490 A JP2004565490 A JP 2004565490A JP 2006514054 A5 JP2006514054 A5 JP 2006514054A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- alkyl
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 37
- 239000000203 mixture Substances 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 238000006467 substitution reaction Methods 0.000 claims 10
- -1 —OR 4 Chemical group 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims 3
- 229940122117 Potassium channel agonist Drugs 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 101710088194 Dehydrogenase Proteins 0.000 claims 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims 2
- 108010044467 Isoenzymes Proteins 0.000 claims 2
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims 2
- 102000004317 Lyases Human genes 0.000 claims 2
- 108090000856 Lyases Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims 2
- 229940123934 Reductase inhibitor Drugs 0.000 claims 2
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 claims 2
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 claims 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 230000003656 anti-hair-loss Effects 0.000 claims 2
- 239000000051 antiandrogen Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 229960000997 bicalutamide Drugs 0.000 claims 2
- 239000003124 biologic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229960002074 flutamide Drugs 0.000 claims 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 2
- 239000002474 gonadorelin antagonist Substances 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229960002613 tamsulosin Drugs 0.000 claims 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims 2
- 229960001693 terazosin Drugs 0.000 claims 2
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 claims 1
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 claims 1
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 claims 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical group NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108010065942 Prostaglandin-F synthase Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010071019 Prostatic dysplasia Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960004199 dutasteride Drugs 0.000 claims 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims 1
- 229960004039 finasteride Drugs 0.000 claims 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 229960003632 minoxidil Drugs 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 230000003658 preventing hair loss Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43410102P | 2002-12-17 | 2002-12-17 | |
| PCT/US2003/039863 WO2004060488A1 (en) | 2002-12-17 | 2003-12-15 | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006514054A JP2006514054A (ja) | 2006-04-27 |
| JP2006514054A5 true JP2006514054A5 (https=) | 2006-12-28 |
| JP4585320B2 JP4585320B2 (ja) | 2010-11-24 |
Family
ID=32713010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004565490A Expired - Fee Related JP4585320B2 (ja) | 2002-12-17 | 2003-12-15 | 男性ホルモン依存性疾患の処置のための１７β−ヒドロキシステロイドデヒドロゲナーゼ３型インヒビター |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7053091B2 (https=) |
| EP (1) | EP1572299B1 (https=) |
| JP (1) | JP4585320B2 (https=) |
| CN (1) | CN1744930A (https=) |
| AT (1) | ATE409065T1 (https=) |
| AU (1) | AU2003293555A1 (https=) |
| CA (1) | CA2509758A1 (https=) |
| DE (1) | DE60323765D1 (https=) |
| ES (1) | ES2312845T3 (https=) |
| MX (1) | MXPA05006485A (https=) |
| WO (1) | WO2004060488A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60323765D1 (de) * | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
| EA015517B1 (ru) * | 2004-04-13 | 2011-08-30 | Инсайт Корпорейшн | Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора |
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| US8036244B2 (en) * | 2004-08-06 | 2011-10-11 | Sharp Kabushiki Kaisha | Transmitter, receiver, communication system, communication method, non-transitory computer readable medium |
| CA2964111A1 (en) | 2005-03-29 | 2006-10-05 | The Trustees Of The University Of Pennsylvania | Methods for generating new hair folicles, treating baldness, and hair removal |
| GB0513702D0 (en) * | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| WO2007130712A1 (en) * | 2006-01-31 | 2007-11-15 | Janssen Pharmaceutica, Nv | Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| CN102369186B (zh) | 2009-04-02 | 2014-07-09 | 默克专利有限公司 | 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物 |
| AU2011338530B2 (en) | 2010-12-06 | 2017-06-15 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| JP6556125B2 (ja) | 2013-06-25 | 2019-08-07 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての治療的に活性な１７−窒素置換エストラトリエンチアゾール誘導体 |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| DE102014005129A1 (de) | 2014-04-08 | 2014-11-06 | Daimler Ag | Verfahren und Fahrerassistenzvorrichtung zur Unterstützung eines Fahrers beim Führen eines Fahrzeugs |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | １７β‐ＨＳＤ１抑制剤のプロドラッグ |
| CN105461705B (zh) * | 2015-11-30 | 2018-04-10 | 中国医科大学 | 二苯并氮杂卓二酮类抗肿瘤化合物及其制备方法 |
| UA124972C2 (uk) | 2016-07-29 | 2021-12-22 | Янссен Фармацевтика Нв | Способи лікування раку передміхурової залози |
| HRP20240679T1 (hr) | 2017-06-08 | 2024-08-16 | Organon R&D Finland Ltd | 17-oksimi 15.beta.-[3-propanamido]-supstituiranih etera-1,3,5(10)-trien-17-ona za uporabu u inhibiciji 17.beta.-hidroksisteroid dehidrogenaza |
| JP7417608B2 (ja) | 2018-12-05 | 2024-01-18 | フォレンド ファーマ リミテッド | １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物 |
| CN112321515A (zh) * | 2020-10-21 | 2021-02-05 | 上海馨远医药科技有限公司 | 一种手性1-叔丁基-3-甲基-6-甲基哌嗪-1,3-二甲酸酯的制备方法 |
| CN112321538A (zh) * | 2020-10-28 | 2021-02-05 | 都创(上海)医药开发有限公司 | 一种合成单胺保护的哌嗪-（r/s）2-甲酸酯的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58836B1 (en) | 1984-08-02 | 1993-11-17 | Labrie Fernand | Pharmaceutical composition for combination therapy of hormone dependent cancers |
| ZA901847B (en) | 1989-03-10 | 1991-10-30 | Endorecherche Inc | Combination therapy for the treatment of estrogen sensitive diseases |
| ATE230994T1 (de) | 1989-07-07 | 2003-02-15 | Endorech Inc | Methode zur behandlung androgenbedingter krankheiten |
| DE69034148T2 (de) | 1989-07-07 | 2005-06-30 | Endorecherche Inc., Ste-Foy | Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| ATE197458T1 (de) | 1993-05-17 | 2000-11-11 | Endorech Inc | Verbesserte antiandrogene |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| HUP0101809A3 (en) | 1998-03-11 | 2002-07-29 | Endorech Inc Sainte Foy | Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use |
| CN1129581C (zh) * | 1998-09-22 | 2003-12-03 | 山之内制药株式会社 | 氰基苯基衍生物 |
| TR200101754T2 (tr) * | 1998-12-18 | 2002-05-21 | Schering Corporation | Farnezil protein transferaz inhibitörleri |
| US6362188B1 (en) * | 1998-12-18 | 2002-03-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
| PE20030703A1 (es) | 2001-09-06 | 2003-08-21 | Schering Corp | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 |
| EP1436281B1 (en) * | 2001-10-17 | 2010-06-16 | Schering Corporation | Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| WO2004046111A1 (en) | 2002-11-18 | 2004-06-03 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| DE60323765D1 (de) * | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
-
2003
- 2003-12-15 DE DE60323765T patent/DE60323765D1/de not_active Expired - Lifetime
- 2003-12-15 CN CNA2003801094364A patent/CN1744930A/zh active Pending
- 2003-12-15 JP JP2004565490A patent/JP4585320B2/ja not_active Expired - Fee Related
- 2003-12-15 US US10/735,983 patent/US7053091B2/en not_active Expired - Fee Related
- 2003-12-15 WO PCT/US2003/039863 patent/WO2004060488A1/en not_active Ceased
- 2003-12-15 MX MXPA05006485A patent/MXPA05006485A/es active IP Right Grant
- 2003-12-15 CA CA002509758A patent/CA2509758A1/en not_active Abandoned
- 2003-12-15 EP EP03790505A patent/EP1572299B1/en not_active Expired - Lifetime
- 2003-12-15 AT AT03790505T patent/ATE409065T1/de not_active IP Right Cessation
- 2003-12-15 AU AU2003293555A patent/AU2003293555A1/en not_active Abandoned
- 2003-12-15 ES ES03790505T patent/ES2312845T3/es not_active Expired - Lifetime
-
2006
- 2006-02-23 US US11/360,711 patent/US7271175B2/en not_active Expired - Fee Related
-
2007
- 2007-08-09 US US11/836,530 patent/US7485645B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514054A5 (https=) | ||
| JP2006513169A5 (https=) | ||
| CA2506290C (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
| MX2023006883A (es) | Metodos para tratar el cancer de prostata. | |
| EA200101223A1 (ru) | Новые соединения, их применение и получение | |
| JP2014500870A5 (https=) | ||
| ATE355275T1 (de) | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| AU2492500A (en) | Aspartic protease inhibitors, compositions, and associated therapeutic methods | |
| AP1816A (en) | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists. | |
| IS5588A (is) | Æxliseyðandi miðlar | |
| WO2004084812A3 (en) | Tamandarin analogs and fragments thereof and methods of making and using | |
| JP2012500778A5 (https=) | ||
| JO2413B1 (en) | Benzoxazine derivatives and their use | |
| ATE429429T1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| SG145570A1 (en) | 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| AU2002364953A8 (en) | Topoisomerase poison agents | |
| TW200420559A (en) | Amine compounds and method for producing the same | |
| WO2004014906A3 (en) | Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents | |
| TW200811100A (en) | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | |
| JP2004502773A5 (https=) | ||
| ATE229538T1 (de) | 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose | |
| DE602004026571D1 (en) | Cyclisches aminophenylsulfamatderivativ | |
| DE69725167D1 (de) | N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung |